Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Figà-Talamanca, L.
Right arrow Articles by Russo, F. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Figà-Talamanca, L.
Right arrow Articles by Russo, F. L.
NEUROLOGY 1985;35:258
© 1985 American Academy of Neurology

Hyperthermia after discontinuance of levodopa and bromocriptine therapy

Impaired dopamine receptors a possible cause

Ladislao Figà-Talamanca, MD, Carla Gualandi, MD, Luciana Di Meo, MD, Giancarlo Di Battista, MD, Giuseppe Neri, MD and Francesca Lo Russo, MD

From Divisione di Neurologia, Ospedale S. Filippo Neri, Rome. Italy.

Hyperthermia, with no signs of any underlying infection, may occur in the course of neuroleptic malignant syndrome, fatal catatonia, heat stroke, or malignant hyperthermia. We describe hyperthermia as a complication after discontinuance of antiparkinsonian treatment with levodopa/carbidopa and bromocriptine. Impaired nigrostriatal, hypothalamic, and mesolimbic dopaminergic functions could be involved in pathogenesis.

Address correspondence and reprint requests to Dr. Figà-Talamanca. Divisione di Neurolngia, Ospedale S. Filippo Neri. Via Martinotti 20, 00135 Rome. Italy.

Accepted for publication May 15. 1984




This article has been cited by other articles:


Home page
 NeurologyHome page
F. J.G. Vingerhoets, J.-G. Villemure, P. Temperli, C. Pollo, E. Pralong, and J. Ghika
Subthalamic DBS replaces levodopa in Parkinson's disease: Two-year follow-up
Neurology, February 12, 2002; 58(3): 396 - 401.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
D. L. Keyser and R. L. Rodnitzky
Neuroleptic Malignant Syndrome in Parkinson's Disease After Withdrawal or Alteration of Dopaminergic Therapy
Arch Intern Med, April 1, 1991; 151(4): 794 - 796.
[Abstract] [PDF]

Home page
 JAMAHome page
J. H. Friedman, S. S. Feinberg, and R. G. Feldman
A Neuroleptic Malignantlike Syndrome due to Levodopa Therapy Withdrawal
JAMA, November 15, 1985; 254(19): 2792 - 2795.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by AAN Enterprises, Inc.